VistaGen Therapeutics, Inc. Capital Expenditures

Capital Expenditures of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital Expenditures for the quarter ending December 30, 2020 was $-151 Thousand (a 52.94% increase compared to previous quarter)
  • Year-over-year quarterly Capital Expenditures decreased by -Infinity%
  • Annual Capital Expenditures for 2019 was $-174 Thousand (a 10775.0% increase from previous year)
  • Annual Capital Expenditures for 2018 was $-1.6 Thousand (a -99.33% decrease from previous year)
  • Annual Capital Expenditures for 2017 was $-239 Thousand (a 809.13% increase from previous year)
  • Twelve month Capital Expenditures ending December 30, 2020 was $-254 Thousand (a 7.03% increase compared to previous quarter)
  • Twelve month trailing Capital Expenditures increased by 49.65% year-over-year
Trailing Capital Expenditures for the last four month:
30 Dec '20 29 Sep '20 30 Mar '19 30 Dec '18
$-254 Thousand $-237 Thousand $-174 Thousand $-170 Thousand
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Expenditures of VistaGen Therapeutics, Inc.

Most recent Capital Expendituresof VTGN including historical data for past 10 years.

Interactive Chart of Capital Expenditures of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Capital Expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.15 $-0.1
2019 $-0.0 $-0.17
2018 $0.0 $-0.13 $-0.04 $0.0 $-0.0
2017 $0.0 $-0.0 $-0.23 $-0.24
2016 $-0.0 $-0.01 $-0.0 $-0.02 $-0.03
2015 $-0.0
2014 $0.0 $-0.01
2013 $0.02 $-0.02 $-0.01 $-0.0 $-0.14
2012 $-0.13 $-0.02 $-0.03
2011 $-0.01 $-0.01 $-0.06 $-0.06
2010 $0.0 $-0.01

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.